Guidelines of the Polish Psychiatric Association – Wroclaw Division, the Polish Society of Family Medicine and the College of Family Physicians in Poland for diagnosis and treatment of depressive disorders in primary health care

• Authors: Piotrowski Patryk , Gondek Tomasz , Rymaszewska Joanna , Beszłej Jan , Czachowski Sławomir , Parmentier Henryk , Kurpas Donata
• Languages of publication: EN

Keywords

EN

primary health care; depression; mood disorders; antidepressant treatment.

• Publisher: Stowarzyszenie Przyjaciół Medycyny Rodzinnej i Lekarzy Rodzinnych
• Journal: Family Medicine & Primary Care Review
• Year: 2017
• Issue: 3
• Pages: 335-346

Contributors

author

Piotrowski Patryk

author

Gondek Tomasz

author

Rymaszewska Joanna

author

Beszłej Jan

author

Czachowski Sławomir

author

Parmentier Henryk

author

Kurpas Donata

References

• Murray CJ L, Lopez AD , eds. The Global Burden of Disease: a comprehensive assessment of mortality and disability from diseases, injuries,and risk factors in 1990 and projected to 2020. Cambridge: H arvard University Press; 1996.
• Murray CJ, Vos T , L ozano R , et al. D isability-adjusted life years (DAL Ys) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of D isease S tudy 2010. Lancet 2012; 380(9859): 2197–2223.
• Alonso J, A ngermeyer M C, Bernert S , et al. Prevalence of mental disorders in E urope: results from the E uropean S tudy of the E pidemiology of M ental D isorders (ESEM eD) project. Acta Psychiatr Scand 2004; S uppl. 109(420): 21–27.
• Bromet E J, Gluzman S F, Paniotto VI, et al. E pidemiology of psychiatric and alcohol disorders in Ukraine: findings from the Ukraine W orld Mental H ealth survey. Soc Psychiatry Psychiatr Epidemiol 2005; 40(9): 681–690
• Moskalewicz J, K iejna A , W ojtyniak B, eds. Kondycja psychiczna mieszkańców Polski. W arszawa: I PiN; 2012: 186 (in Polish).
• Roca M , Gili M , Garcia-Garcia M , et al. Prevalence and comorbidity of common mental disorders in primary care. J Affect Disord 2009;119(1–3): 52–58.
• Ansseau M , D ierick M , Buntinkx F, et al. H igh prevalence of mental disorders in primary care. J Affect Disord 2004; 78(1): 49–55.
• Montago CB. R ecognition and treatment of depression in a primary care setting. J Clin Psychiatry 1994; 55(Suppl.): 18–34; discussion
• Scott KM , Bruffaerts R , T sang A , et al. D epression–anxiety relationships with chronic physical conditions: results from the W orld M ental Health S urveys. J Affect Disord 2007; 103(1–3): 113–120.
• Katon W , L in EH B, K roenke K . T he association of depression and anxiety with medical symptom burden in patients with chronic medical illness. Gen Hosp Psychiatry 2007; 29(2): 147–155.
• Härter M , Baumeister H , R euter K , et al. I ncreased 12-month prevalence rates of mental disorders in patients with chronic somatic disease. Psychother Psychosom 2007; 76(6): 354–360.
• Dudek D , S iwek M . W spółistnienie chorób somatycznych i depresji. Psychiatria 2007; 4(1): 17–24 (in Polish).
• Barley EA , M urray J, W alters P, et al. M anaging depression in primary care: a meta-synthesis of qualitative and quantitative research from UK to identify barriers and facilitators. BMC Family Practice 2011; 12: 47–57.
• Egede LE . M ajor depression in individuals with chronic medical disorders: prevalence, correlates and association with health resource utilization, lost productivity and functional disability. Gen Hosp Psychiatry 2007; 29(5): 409–416.
• Simon GE, K aton W J, L in EH , et al. Cost-effectiveness of systematic depression treatment among people with diabetes mellitus. Arch Gen Psychiatry 2007; 64(1): 65–72.
• Scott KM , Von K orkoff M , A lonso J, et al. M entalphysical co-morbidity and its relationship with disability: results from the W orld M ental Health S urveys. Psychol Med 2009; 39(1): 33–43.
• Dróżdż W , W ojnar M , A raszkiewicz A , et al. T he study of the prevalence of depressive disorders in primary care patients in Poland. Wiad Lek 2007; 60(3–4): 109–113.
• Tylee A , Gandhi P. T he importance of somatic symptoms in depression in primary care. Prim Care Companion J Clin Psychiatry 2005;7(4): 167–176.
• Klasyfikacja zaburzeń psychicznych i zaburzeń zachowania w ICD-10. Badawcze kryteria diagnostyczne. K raków, W arszawa: Uniwersyteckie W ydawnictwo M edyczne „Vesalius”, I nstytut Psychiatrii i Neurologii; 1998 (in Polish).
• Whooley MA , A vins AL , M iranda J, et al. Case-finding instruments for depression: two questions are as good as many. J Gen Intern Med 1997; 12(7): 439–445.
• Arroll B, K hin N , K erse N . S creening for depression in primary care with two verbally asked questions: cross sectional study. BMJ 2003;327(7424): 1144–1146.
• Arroll B, Goodyear-Smith F, K erse N , et al. E ffect of the addition of a “help” question to two screening questions on specificity for diagnosis of depression in general practice: diagnostic validity study. BMJ 2005; 331(7521): 884.
• Mitchell A J, Coyne JC. D o ultra-short screening instruments accurately detect depression in primary care? A pooled analysis and metaanalysis of 22 studies. Br J Gen Pract 2007; 57(535): 144–151.
• Kroenke K , S pitzer RL , W illiams JB. T he PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16(9): 606–613.
• Zigmond AS , S naith R P. T he hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67(6): 361–370.
• Beck AT , S teer RA , Ball R , et al. Comparison of Beck D epression I nventories-IA and-II in psychiatric outpatients. J Pers Assess 1996;67(3): 588–597.
• Sutor B. M ajor depression in medically ill patients. Mayo Clin Proc 1998; 73(4): 329–337.
• Lehtinen V, Joukamaa M . E pidemiology of depression: prevalence, risk factors and treatment situation. Acta Psychiatr Scand 1994;Suppl. 377: 7–10.
• Kendler KS , Gardner CO, N eale M C, et al. Genetic risk factors for major depression in men and women: similar or different heritabilities and same or partly distinct genes? Psychol Med 2001; 31(4): 605–616.
• Kranzler HR , R osenthal RN . D ual diagnosis: alcoholism and co-morbid psychiatric disorders. Am J Addict 2003; 12(Suppl. 1): S 26–S40.
• Bovasso GB. Cannabis abuse as a risk factor for depressive symptoms. Am J Psychiatry 2001; 158(12): 2033–2037.
• Davis L , Uezato A , N ewell JM, et al. M ajor depression and comorbid substance use disorders. Curr Opin Psychiatry 2008; 21(1): 14–18.
• Kiejna A , Piotrowski P, A damowski T , et al. T he prevalence of common mental disorders in the population of adult Poles by sex and age structure – an EZO P Poland study. Psychiatr Pol 2015; 49(1): 15–27.
• Hawton K , Casañas I , Comabella C, et al. R isk factors for suicide in individuals with depression: a systematic review. J Affect Disord 2013; 147(1–3): 17–28.
• Masiak M , Przychoda J. M.I.N.I. Mini International Neuropsychiatric Interview. Polish Version 5.0.0. L ublin: K atedra i Klinika Psychiatrii Akademii M edycznej; 1998 (in Polish).
• Rouchell AM . M ajor depression in primary care. Ochsner J 2000; 2(2): 79–84.
• Hage M P, A zar ST . T he link between thyroid function and depression. J Thyroid Res 2012; 2012: 590648, doi: 10.1155/2012/590648.
• Dayan CM, Panicker V. H ypothyroidism and depression. Eur Thyroid J 2013; 2(3): 168–179, doi: 10.1159/000353777.
• De Picker L , Van D en E ede F, D umont G, et al. A ntidepressants and the risk of hyponatremia: a class-by-class review of literature. Psychosomatics 2014; 55(6): 536–547.
• Beach SR , K ostis W J, Celano CM, et al. M eta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation. J Clin Psychiatry 2014; 75(5): e441–e449.
• Wang PS, Bohn RL , K night E , et al. N oncompliance with antihypertensive medications: the impact of depressive symptoms and psychosocial factors. J Gen Intern Med 2002; 17(7): 504–511.
• Gentil L , Vasiliadis HM , Préville M , et al. A dherence to oral antihyperglycemic agents among older adults with mental disorders and its effect on health care costs, Quebec, Canada, 2005–2008. Prev Chronic Dis 2015; 12: 150412, doi: http://dx.doi.org/10.5888/pcd12.150412.
• Michal M , Prochaska JH, Ullmann A , et al. R elevance of depression for anticoagulation management in a routine medical care setting:results from the T hrombEVAL study program. J Thromb Haemost 2014; 12(12): 2024–2033.
• Mausbach BT, S chwab R B, I rwin SA . D epression as a predictor of adherence to adjuvant endocrine therapy (AET ) in women with breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat 2015; 152(2): 239–246.
• Müller VI, Cieslik E C, S erbanescu I , et al. A ltered brain activity in unipolar depression revisited: meta-analyses of neuroimaging studies.JAMA Psychiatry 2017; 74(1): 47–55.
• Dougherty DD , R auch SL , eds. Psychiatric neuroimaging research: contemporary strategies. W ashington D C: A merican Psychiatric Publishing I nc.; 2001.
• Sheehan D V, L ecrubier Y, S heehan KH , et al. T he M ini-International N europsychiatric I nterview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM -IV and I CD-10. J Clin Psychiatry 1998; 59(Suppl. 20): 22–33, quiz 34–57.
• Tamburrino M B, L ynch D J, N agel RW , et al. Primary Care E valuation of M ental D isorders (PRIME -MD ) screening for minor depressive disorder in primary care. Prim Care Companion J Clin Psychiatry 2009; 11(6): 339–343.
• Tomaszewski K , Z arychta M , Bieńkowska A , et al. Validation of the Patient H ealth Questionnaire-9 Polish version in the hospitalised elderly population. Psychiatr Pol 2011; 45(2): 223–233.
• Arroll B, Goodyear-Smith F, Crengle S , et al. Validation of PHQ-2 and PHQ-9 to screen for major depression in the primary care population.Ann Fam Med 2010; 8(4): 348–353, doi: 10.1370/afm.1139.
• Perris C. A study of bipolar (manic-depressive) and unipolar recurrent depressive psychoses. Genetic investigation. Acta Psychiatr Scand 1966; 42(Suppl. 194): 15–44.
• Angst J. Zur Atiologie und Nosologie endogener depressiver Psychosen. Berlin: S pringer; 1966.
• Akiskal HS . T he prevalent clinical spectrum of bipolar disorders: beyond DSM -IV. J Clin Psychopharmacol 1996; 16(Suppl. 1): 4–14.
• Ghaemi SN , K o JY, Goodwin FK. T he bipolar spectrum and the antidepressant view of the world. J Psychiatr Pract 2001; 7(5): 287–297.
• Merikangas KR , Jin R , H e JP, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative.Arch Gen Psychiatry 2011; 68(3): 241–251.
• Łojko D , R ybakowski J, D udek D , et al. H ypomania Check L ist (HCL-32) – kwestionariusz objawów hipomanii: charakterystyka i zastosowanie.Psychiatr Pol 2010; 44(1): 39–46 (in Polish).
• Perlis RH , Brown E , Baker RW , et al. Clinical features of bipolar depression versus major depressive disorder in large multicenter trials.Am J Psychiatry 2006; 163(2): 225–231
• Jacob S , S pinler SA . H yponatremia associated with selective serotonin-reuptake inhibitors in older adults. Ann Pharmacother 2006;40(9): 1618–1622.
• Dalton SO , Johansen C, M ellemkjaer L , et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med 2003; 163(1): 59–64
• National I nstitute of Clinical E xcellance. D epression: management of depression in primary and secondary care – clinical guidance 2004 [cited: 13.04.2017]. A vailable from URL : http://www.nice.org.uk.
• Committee on S afety of M edicines. R eport of the CSM expert working group on the safety of selective serotonin reuptake inhibitor antidepressants 2004 [cited: 13.04.2017]. A vailable from URL : http://www.mhra.gov.uk.
• NI CE. 1.8 S equencing treatments after initial inadequate response [cited: 13.04.2017]. A vailable from URL : https://www.nice.org.uk/guidance/cg90/chapter/1-Guidance#treatment-choice-based-on-depression-subtypes-and-personal-characteristics.
• Loonen A J, Peer PGM, Z wanikken GJ. Continuation and maintenance therapy with antidepressive agents. M eta-analysis of research.Pharm Weekley Sci 1991; 13(4): 167–175.
• Haddad PM. A ntidepressant discontinuation syndromes. Drug Saf 2001; 24(3): 183–197.
• Ashton H . T he diagnosis and management of benzodiazepine dependence. Curr Opin Psychiatry 2005; 18(3): 249–255.
• Basińska A . Z apobieganie uzależnieniom od benzodiazepin i nie-benzodiazepinowych leków nasennych – regulacje prawne i zalecenia medyczne. Terapia 2011; 19: 66–70 (in Polish).
• Montgomery SA , Pedersen V, T anghøj P, et al. T he optimal dosing regimen for citalopram – a meta-analysis on nine placebo-controlled studies. Int Clin Psychopharmacol 1994; 9(Suppl. 1): 35–40.
• Kennedy SH , A vedisova A , Belaïdi C, et al. S ustained efficacy of agomelatine 10 mg, 25 mg, and 25–50 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months. Eur Neuropsychopharmacol 2016; 26(2): 378–389, doi: 10.1016/j.euroneuro.2015.09.006.
• Burke W J, Gergel I , Bose A . Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002;63(4): 331–336.
• Goldstein D J, L u Y, D etke M J, et al. D uloxetine in the treatment of depression, a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 2004; 24(4): 389–399.
• Detke M J, L u Y, Goldstein D J, et al. D uloxetine, 60 mg once daily for major depressive disorder: a randomized double-blind placebocontrolled trail. J Clin Psychiatry 2002; 63(4): 308–315.
• Altamura A C, M ontgomery SA , W ernicke JF. T he evidence for 20 mg a day of fluoxetine as the optimal dose in the treatment of depression.Br J Psychiatry 1988; 3(Suppl.): 109–112
• Wakeling A . E fficacy and side effects of mianserin, a tetracyclic antidepressant. Postgrad Med J 1983; 59(690): 229–231.
• Walczak DD , A pter JT, H alikas JA, et al. T he oral dose-effect relationship for fluvoxamine: a fixed-dose comparison against placebo in depressed outpatients. Ann Clin Psychiatry 1996; 8(3): 139–151.
• Van M offaert M , de W ilde J, Vereecken A , et al. M irtazapine is more effective than trazodone: a double-blind controlled study in hospitalized patients with major depression. Int Clin Psychopharmacol 1995; 10(1): 3–9.
• Dunner DL , D unbar GC. O ptimal dose regimen for paroxetine. J Clin Psychiatry 1992; 53(Suppl.): 21–26.
• Priest R G, S chmid-Burgk W . M oclobemide in the treatment of depression. Rev Contemp Pharmacother 1994; 5: 35–43.
• Moon CAL , et al. A double-blind comparison of sertraline and clomipramine in the treatment of major depressive disorder and associative anxiety in general practice. J Psychopharmacol 1994; 8: 171–176.
• Brogden RN , H eel R C, S peight TM , et al. T razodone: a review of its pharmacological properties and therapeutic use in depression and anxiety. Drugs 1981; 21(6): 401–429.
• Feigher JP, E ntsuah AR , M cPherson MK . E fficacy of once-daily venlafaxine extended release (XR) for symptoms of anxiety in depressed outpatients. J Affect Disord 1998; 47(1–3): 55–62.
• Gravem A , A mthor K F, A strup C, et al. A double-blind comparison of citalopram (Lu 10-171) and amitriptyline in depressed patients.Acta Psychiatr Scand 1987; 75(5): 478–486.
• Andersen J, Bech P, Benjaminsen S , et al. Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicentre study. Psychopharmacology 1986; 90: 131–138.
• Volz H P, M öller H J, R eimann I , et al. O pipramol for the treatment of somatoform disorders results from a placebo-controlled trial.D Eur Neuropsycopharmacol 2000; 10: 211
• Kupfer D J. T he pharmacological management of depression. Dialogues Clin Neurosci 2005; 7(3): 191–205.
• Baldwin DS , Chrones L , Florea I , et al. T he safety and tolerability of vortioxetine: analysis of data from randomized placebo-controlled trials and open-label extension studies. J Psychopharmacol (Oxford) 2016; 30(3): 242–252, doi: 10.1177/0269881116628440.
• meta-analysis of randomized–controlled trials comparison with venlafaxine. Drug Des Devel Ther 2013; 7: 1053–1062, doi: 10.2147/DDDT .S46849
• Zimmerman M , M cGlinchey JB, Posternak MA , et al. H ow should remission from depression be defined? T he depressed patient’s perspective. Am J Psychiatry 2006; 163(1): 148–150.